Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs) Ulrich Klotz Editorial Commentary 29 October 2008 Pages: 1 - 2
Chronic heart failure: β-blockers and pharmacogenetics Junichi AzumaShinpei Nonen Review Article 07 October 2008 Pages: 3 - 17
Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH Julia KirchheinerSilke GlattJürgen Brockmöller Review Article 17 October 2008 Pages: 19 - 31
Limits of add-on trials: antirheumatic drugs Laura OttolenghiVittorio Bertele’Silvio Garattini Clinical Trial 03 September 2008 Pages: 33 - 41
Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden Elisabet EkmanM. Bäckström Special Article 30 September 2008 Pages: 43 - 46
Mesalazine pharmacokinetics and NAT2 phenotype Hendrik LückMartina KinzigFritz Sörgel Pharmacogenetics 14 August 2008 Pages: 47 - 54
Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism Horng-Yuan LouChun-Chao ChangHsiu-O Ho Pharmacogenetics 27 August 2008 Pages: 55 - 64
Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects Rui LiuAudrey May Yi TangEdmund Jon Deoon Lee Pharmacogenetics 03 September 2008 Pages: 65 - 70
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients Doaa ElsherbinyKaren CohenUlrika S. H. Simonsson Pharmacokinetics and Disposition 27 August 2008 Pages: 71 - 80
No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers Silke C. MuellerJolanta Majcher-PeszynskaBernd Drewelow Pharmacokinetics and Disposition 03 September 2008 Pages: 81 - 87
Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib Ville V. HynninenKlaus T. OlkkolaKari Laine Pharmacokinetics and Disposition 09 September 2008 Pages: 89 - 95
Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual Andrea GaedigkDorothee FrankUwe Fuhr Short Communication 17 September 2008 Pages: 97 - 100
High serum concentrations of ciclosporin related to administration of tigecycline Anita N. StumpfChristian SchmidtArmin Gerbitz Letter to the Editors Open access 16 September 2008 Pages: 101 - 103
Cytochrome P450 and gene activation – cholesterol elimination and regression of atherosclerosis: author reply to the commentary Pauli V. Luoma Letter to the Editors 25 September 2008 Pages: 105 - 106
Aggregated and individual pharmacy record data. Association between antibiotic and antihypertensive drug use J. Lars G. NilssonGunnar LindbergArne Melander Letter to the Editors 11 October 2008 Pages: 107 - 108